Sarepta Therapeutics Income Statement - Quarterly (NASDAQ:SRPT)

Add to My Stocks
$42.54 $1.41 (3.21%) SRPT stock closing price Jul 25, 2017 (Closing)

SRPT stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Sarepta Therapeutics stock price. In the income statement, an investor can look at important parameters like revenue, gross profits, net profits, and EPS basic to gain deeper insights. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has grown from $16.34M to $35.01M and how operating and non operating activities have impacted the SRPT stock. Along with Sarepta Therapeutics assets and Sarepta Therapeutics free cash flow, profits as shown in profit and loss statement give key insights about the business. The profits have decreased from $84.09M QoQ and 2017-Q2 revenue is $35.01M. View details of revenue and profits for Sarepta Therapeutics for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1
Sarepta Therapeutics Net Sales or Revenues
35.01M16.34M5.42M---1.25M---
Cost Of Goods Sold (COGS)-0.25M--------
Sarepta Therapeutics Gross Profit
-16.09M----1.25M---
Research & Development Expense-29.11M70.75M34.34M-38.82M41.38M36.67M29.18M39.16M
Selling General & Admin Expense-26.21M22.94M22.18M-20.87M24.34M15.09M12.92M22.69M
Income Before Depreciation Depletion Amortization--39.24M-93.69M-56.53M--59.7M-64.46M-51.76M-42.1M-61.86M
Depreciation Depletion Amortization----------
Non Operating Income-125.33M-0.06M-0.2M--0.06M-0.23M-0.17M0.25M0.3M
Interest Expense----------
Sarepta Therapeutics Pretax Income
-86.09M-88.45M-56.74M--59.77M-64.7M-51.93M-41.85M-61.55M
Provision for Income Taxes-2M--------
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-63.05M84.09M-88.45M-56.74M-62.3M-59.77M-64.68M-51.94M-41.85M-61.56M
Extraordinary Items & Discontinued Operations----------
Sarepta Therapeutics Net Income (Profit/Loss)
-63.05M84.09M-88.45M-56.74M-62.3M-59.77M-64.68M-51.94M-41.85M-61.56M
Average Shares used to compute Diluted EPS54.98M56.01M54.62M48.25M46.16M45.7M44.88M41.57M41.36M41.32M
Average Shares used to compute Basic EPS54.98M54.85M54.62M48.25M46.16M45.7M44.88M41.57M41.36M41.32M
Income Before Nonrecurring Items-63.05M-40.91M-86.31M-56.74M-62.3M-59.77M-64.68M-51.94M-41.85M-61.56M
Income from Nonrecurring Items-125M-2.14M-------
Sarepta Therapeutics Earnings Per Share Basic Net
-1.151.53-1.62-1.18-1.35-1.31-1.44-1.25-1.01-1.49
Sarepta Therapeutics Earnings Per Share Diluted Net
-1.151.50-1.62-1.18-1.35-1.31-1.44-1.25-1.01-1.49
EPS Diluted Before Nonrecurring Items-1.15-0.73-1.58-1.18-1.35-1.31-1.44-1.25-1.01-1.49
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Income statement for another ticker

1:11
SRPT
It is very helpful to read a report on Sarepta Therapeutics stock analysis. An investor must check the following items in an income statement:
  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth (See: Sarepta Therapeutics revenue chart) implies that the company is growing, which has been the case with Sarepta Therapeutics. One must stay away from stocks whose revenues are declining.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-63.05M for Sarepta Therapeutics for 2017-Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.
The income statement is also called the profit and loss statement. Apart from the income statement, one can check the Sarepta Therapeutics historical stock prices to check how the price has moved with time. .

Sarepta Therapeutics Income Statement - Key Financial Ratios

PS ratio (
price sales ratio
)
41.1987
Operating margin
-240.1
Net profit margin
514.6
Dividend yield
0%